MBX Biosciences (MBX) Non-Current Assets (2023 - 2026)

MBX Biosciences has reported Non-Current Assets for 4 years, with the latest figure at $4.2 million in Q1 2026.

• Quarterly Non-Current Assets rose 152.42% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 161.68% YoY) and the FY2025 annual result came in at $3.6 million, up 188.63% from the prior year.
• Non-Current Assets improved to $4.2 million in Q1 2026 per MBX's latest filing, from $3.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $4.2 million in Q1 2026 and troughed at $715000.0 in Q4 2023.
• A 4-year average of $2.2 million and a median of $2.0 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 74.69% in 2024, then surged 188.63% in 2025.
• Over 4 years, Non-Current Assets stood at $715000.0 in 2023, then soared by 74.69% to $1.2 million in 2024, then soared by 188.63% to $3.6 million in 2025, then rose by 15.53% to $4.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $4.2 million, $3.6 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.